Development of a Disease-Modifying OA Drug (DMOAD) in Knee Osteoarthritis: The Example of Sprifermin

1. Introduction: OA and unmet clinical need for a DMOAD

2. Past DMOAD drug development

3. Sprifermin, its MOA, and clinical development program

4. Lessons learned, summary, and next steps

^* both are affiliates of Merck KGaA, Darmstadt, Germany

• References

• 1 Hellio Le Graverand MP, Clemmer RS, Redifer P et al. A 2-year randomised, double-blind, placebo-controlled, multicentre study of oral selective iNOS inhibitor, cindunistat (SD-6010), in patients with symptomatic osteoarthritis of the knee. Ann Rheum Dis 2013; 72: 187-195
• 2 Reginster JY, Badurski J, Bellamy N et al. Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial. Ann Rheum Dis 2013; 72: 179-186
• 3 Karsdal MA, Byrjalsen I, Alexandersen P et al. Treatment of symptomatic knee osteoarthritis with oral salmon calcitonin: results from two phase 3 trials. Osteoarthritis Cartilage 2015; 23: 532-543
• 4 Brandt KD, Mazzuca SA. Lessons learned from nine clinical trails of disease modifying osteoarthritis drugs. Arthritis & Rheumatism 2005; 52: 3349-3359